Literature DB >> 8608220

The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro.

L S Rusten1, S D Lyman, O P Veiby, S E Jacobsen.   

Abstract

The present studies investigated the effects of the recently cloned flt3 ligand (FL) on the in vitro growth and differentiation of primitive and committed subsets of human CD34+ bone marrow (BM) progenitor cells. FL alone was a weak growth stimulator of CD34+ BM cells, but synergistically and directly enhanced colony formation in combination with interleukin (IL) 3, granulocyte colony-stimulating factor (G-CSF), CSF-1, granulocyte macrophage (GM) CSF stem cell factor (SCF), and IL-6. FL and SCF were equally effective in stimulating colony formation in combination with IL-3. However, the tri-factor combination of FL + IL-3 + SCF stimulated 2.3-fold and 2.5-fold more colonies than FL + IL-3 and SCF + IL-3, respectively. These additional recruited progenitors appeared to be predominantly located in a primitive (CD71-) subset of the CD34+ progenitors, as 4.5-fold more colonies were formed by CD34+CD71- cells in response to FL + IL-3 + SCF than to FL + IL-3 or SCF + IL-3. Similar findings were observed in serum-containing and serum-deprived cultures. Whereas FL did not enhance burst-forming unit-erythroid (BFU-E) colony formation of CD34+ BM cells in the presence of serum, a low number of BFU-E colonies were formed in response to FL plus erythropoietin (Epo) under serum-deprived conditions. In addition, FL both in serum-containing and serum-deprived cultures stimulated colony formation of more committed myeloid progenitors in CD34+CD71+ BM cells. Thus, FL potently stimulates the growth of primitive and more committed human BM progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608220

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 2.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

3.  Genome-wide association of white blood cell counts in Hispanic/Latino Americans: the Hispanic Community Health Study/Study of Latinos.

Authors:  Deepti Jain; Chani J Hodonsky; Ursula M Schick; Jean V Morrison; Sharon Minnerath; Lisa Brown; Claudia Schurmann; Yongmei Liu; Paul L Auer; Cecelia A Laurie; Kent D Taylor; Brian L Browning; George Papanicolaou; Sharon R Browning; Ruth J F Loos; Kari E North; Bharat Thyagarajan; Cathy C Laurie; Timothy A Thornton; Tamar Sofer; Alexander P Reiner
Journal:  Hum Mol Genet       Date:  2017-03-15       Impact factor: 6.150

Review 4.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

5.  Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand.

Authors:  G Cartron; C Binet; O Hérault; C Cailliot; M C Bernard; M H Estienne; N Clément; Ph Colombat; J Domenech
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

6.  Attenuation of vaccinia virus by the expression of human Flt3 ligand.

Authors:  Kamila Zurkova; Petr Hainz; Jitka Krystofova; Luda Kutinova; Miloslav Sanda; Sarka Nemeckova
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

7.  Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6.

Authors:  Flavia Q Pirih; Megan N Michalski; Sun W Cho; Amy J Koh; Janice E Berry; Eduardo Ghaname; Pachiyappan Kamarajan; Edith Bonnelye; Charles W Ross; Yvonne L Kapila; Pierre Jurdic; Laurie K McCauley
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

8.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

9.  Expression, purification and characterization of the extracellular domain of human Flt3 ligand in Escherichia coli.

Authors:  Xingcheng Zhao; Ping Zhang; Qiang Liu; Fei He; Lei Feng; Hua Han
Journal:  Mol Biol Rep       Date:  2009-08-20       Impact factor: 2.316

Review 10.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

Authors:  Jianbiao Zhou; Boon-Cher Goh; Daniel H Albert; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2009-07-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.